Abstract
BACKGROUND: We have previously found that acute intravenous infusion of an ACE inhibitor normalized the reduced coronary vasomotor function in type 2 diabetes. The aim of the present study was to extend this investigation to an angiotensin II receptor blocker (ARB) administered orally in normotensive, asymptomatic type 2 diabetes patients without albuminuria.
RESULTS: Fourteen type 2 diabetes patients were included. Each patient had myocardial perfusion measured by PET at three occasions: at baseline, following 3 weeks of treatment with 50mg/d and following another 3 weeks of treatment with 100mg/d of losartan. Baseline myocardial perfusion was similar at all three sessions (0.89+/-0.05, 0.90+/-0.08 and 0.84+/-0.05mL/(ming) tissue, respectively). Likewise, maximal hyperaemic perfusion after i.v. dipyridamole (0.56mg/kg bwt) was low but similar at the three sessions (2.01+/-0.14, 2.05+/-0.17 and 1.90+/-0.20mL/(ming) tissue, respectively). Myocardial perfusion reserve, i.e. maximal hyperaemic flow relative to baseline flow, was also low, but similar before and after treatment with losartan (2.36+/-0.24, 2.44+/-0.24 and 2.62+/-0.42mL/(ming) tissue, respectively).
CONCLUSIONS: Oral treatment with an ARB did not normalize coronary vasomotor function in type 2 diabetes patients without cardiovascular disease.
Original language | English |
---|---|
Journal | Diabetes Research and Clinical Practice |
Volume | 84 |
Issue number | 1 |
Pages (from-to) | 34-8 |
Number of pages | 5 |
ISSN | 0168-8227 |
DOIs | |
Publication status | Published - Apr 2009 |
Keywords
- Adult
- Aged
- Angiotensin II Type 1 Receptor Blockers
- Blood Pressure
- Coronary Circulation
- Diabetes Mellitus, Type 2
- Electrocardiography
- Female
- Heart Rate
- Hemodynamics
- Humans
- Losartan
- Male
- Middle Aged
- Positron-Emission Tomography
- Clinical Trial
- Journal Article
- Research Support, Non-U.S. Gov't